Gangrene future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Gangrene}}
{{Gangrene}}


Please help WikiDoc by adding content hereIt's easy!  Click [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{CMG}}; {{AE}} [[User:Edzelco|Edzel Lorraine Co, D.M.D., M.D.]]
 
 
==Overview==
A novel [[gene therapeutic approach]] is currently conducted to promote [[reperfusion]] and [[angiogenesis]] of [[ischemic tissues]], which can help in [[limb salvage]]. Ongoing study on this approach is conducted on mice and it involves the [[intramuscular injection]] of [[adeno-associated virus]]/ ([[AAV]]) [[vector]], and [[E-selectin]].
 
==Future or Investigational Therapies==
*More than 150,000 [[limb amputations]] due to [[gangrene]] are done yearly in the United States, despite [[medical]] and [[surgical interventions]].
*A novel [[gene therapeutic approach]] is currently conducted to promote [[reperfusion]] and [[angiogenesis]] of [[ischemic tissues]], which can help in [[limb salvage]].  
*Ongoing study on this approach is conducted on mice and it involves the [[intramuscular injection]] of [[adeno-associated virus]]/ ([[AAV]]) [[vector]], and [[E-selectin]]. <ref name="pmid34617055">{{cite journal| author=Quiroz HJ, Parikh PP, Lassance-Soares RM, Regueiro MM, Li Y, Shao H | display-authors=etal| title=Gangrene, revascularization, and limb function improved with E-selectin/adeno-associated virus gene therapy. | journal=JVS Vasc Sci | year= 2021 | volume= 2 | issue= | pages= 20-32 | pmid=34617055 | doi=10.1016/j.jvssci.2020.10.001 | pmc=8489216 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34617055 }} </ref>
*Another new emerging therapy involves the [[endothelial progenitor cells]] /([[EPC]]) which are commonly derived from [[peripheral blood]] or [[bone marrow]]. <ref name="pmid25078066">{{cite journal| author=Wang ZX, Li D, Cao JX, Liu YS, Wang M, Zhang XY | display-authors=etal| title=Efficacy of autologous bone marrow mononuclear cell therapy in patients with peripheral arterial disease. | journal=J Atheroscler Thromb | year= 2014 | volume= 21 | issue= 11 | pages= 1183-96 | pmid=25078066 | doi=10.5551/jat.23374 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25078066 }} </ref>


==References==
==References==


{{Reflist|2}}
{{Reflist|2}}
[[Category:Signs and symptoms]]
 
[[Category:Surgery]]
[[Category:Surgery]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Intensive care medicine]]
[[Category:Needs content]]
[[Category:Needs content]]
{{WH}}
{{WS}}

Latest revision as of 02:28, 10 April 2022

Gangrene Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gangrene from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gangrene future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gangrene future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gangrene future or investigational therapies

CDC on Gangrene future or investigational therapies

Gangrene future or investigational therapies in the news

Blogs on Gangrene future or investigational therapies

Directions to Hospitals Treating Gangrene

Risk calculators and risk factors for Gangrene future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.


Overview

A novel gene therapeutic approach is currently conducted to promote reperfusion and angiogenesis of ischemic tissues, which can help in limb salvage. Ongoing study on this approach is conducted on mice and it involves the intramuscular injection of adeno-associated virus/ (AAV) vector, and E-selectin.

Future or Investigational Therapies

References

  1. Quiroz HJ, Parikh PP, Lassance-Soares RM, Regueiro MM, Li Y, Shao H; et al. (2021). "Gangrene, revascularization, and limb function improved with E-selectin/adeno-associated virus gene therapy". JVS Vasc Sci. 2: 20–32. doi:10.1016/j.jvssci.2020.10.001. PMC 8489216 Check |pmc= value (help). PMID 34617055 Check |pmid= value (help).
  2. Wang ZX, Li D, Cao JX, Liu YS, Wang M, Zhang XY; et al. (2014). "Efficacy of autologous bone marrow mononuclear cell therapy in patients with peripheral arterial disease". J Atheroscler Thromb. 21 (11): 1183–96. doi:10.5551/jat.23374. PMID 25078066.

Template:WH

Template:WS